Reperfusion options for acute pulmonary embolism
Official title: Reperfusion Treatment in Acute Pulmonary Embolism: A Multicenter Observational Study in the Nordic Countries
Run by Sahlgrenska University Hospital · NCT07003646 · Data updated 2026-11-12
This project will try catheter-directed interventions or systemic thrombolysis in adults with acute pulmonary embolism to see which approach leads to better outcomes.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 220 (estimated) |
| Sponsor | Sahlgrenska University Hospital Academic / other |
| Locations | 13 sites (Aarhus and 12 other locations) |
| Status | Recruiting |
| Started | April 1, 2025 |
| Main results expected | May 1, 2028 |
| Study ends | May 1, 2029 |
| Registry record updated | January 21, 2026 |
| Trial ID | NCT07003646 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18 years) with confirmed acute pulmonary embolism who are planned for or have received catheter-directed intervention or systemic thrombolysis, including pregnant women, are eligible.
✕Probably not a fit
Patients undergoing surgical embolectomy as the primary reperfusion treatment or those already enrolled in an interventional catheter-directed trial are not expected to benefit from this observational comparison.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
PE-NORDIC is a multicenter observational effort comparing outcomes for adults with acute pulmonary embolism who receive catheter-directed interventions (including mechanical thrombectomy devices such as FlowTriever® and catheter-directed thrombolysis) versus systemic thrombolysis. The study will collect real-world data from participating Nordic hospitals on survival, hemodynamic response, and bleeding complications. It is non-randomized and enrolls patients who are planned for or have already received these reperfusion methods, with a waiver of consent allowed if patients die before consent can be obtained. The project aims to describe how current reperfusion strategies perform in routine clinical practice across the region.
Why it matters
Potential benefit: If successful, it could help identify which reperfusion approach provides better survival and fewer serious bleeding complications for patients with high-risk or deteriorating pulmonary embolism.
How similar studies have gone: Industry-sponsored and single-arm trials have shown promising hemodynamic improvements with devices like FlowTriever, but randomized comparisons between catheter-directed interventions and standard care are still limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * All adult patients (≥18 years), including pregnant women, with verified (CTPA, angiography or scintigraphy) acute pulmonary embolism who are planned for, or have received, treatment with catheter directed intervention or systemic thrombolysis * Informed consent (for patients who do not survive before informed consent can be obtained, a waiver of consent applies) Exclusion Criteria: * Ongoing enrolment in interventional catheter directed intervention trial * Surgical embolectomy as primary reperfusion treatment
Where it's running
-
Aarhus University Hospital
Aarhus, Denmark Recruiting -
Rigshospitalet
Copenhagen, Denmark Recruiting -
Odense University Hospital
Odense, Denmark Recruiting -
Sahlgrenska University Hospital
Gothenburg, Sweden Recruiting -
Linköping University Hospital
Linköping, Sweden Recruiting -
Sunderby Hospital
Luleå, Sweden Recruiting
Show 7 more locations
-
Skåne University Hospital
Lund, Sweden Recruiting -
Örebro University Hospital
Örebro, Sweden Recruiting -
Danderyd Hospital
Stockholm, Sweden Recruiting -
Karolinska University Hospital Huddinge
Stockholm, Sweden Recruiting -
Karolinska University Hospital Solna
Stockholm, Sweden Recruiting -
Södersjukhuset
Stockholm, Sweden Recruiting -
Uppsala University Hospital
Uppsala, Sweden Not yet recruiting
Study contacts
- Principal investigator: Kristina Svennerholm, Assoc Prof — Sahlgrenska University Hospital
- Study coordinator: Freyr Einarsson, MD
- Email: freyr.einarsson@vgregion.se
- Phone: +46500 43 10 36
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
TRiP-cast score test in adults with acute lower-limb injuries requiring immobilization
This study tests whether the TRiP(cast) score can predict risk of blood clots in adults with acute lower-limb injuries treated as outpatients.
-
Prognostic value of the 2026 AHA/ACC PE classification in ED patients with acute PE
This study tests whether the 2026 AHA/ACC five-category PE classification helps predict 30-day major adverse pulmonary embolism events in adults with acute PE presenting to the ED.
-
Right heart dysfunction in acute pulmonary embolism: can echocardiography help predict risk
This study tests whether transthoracic echocardiography can identify right ventricular dysfunction in adults with acute pulmonary embolism to help gauge risk.
-
Aspiration thrombectomy with the Symphony or Prodigy devices
This project will try the Symphony and Prodigy aspiration thrombectomy devices to remove arterial, venous, or pulmonary blood clots in adults.
-
PERC and YEARS approaches for diagnosing pulmonary embolism in the emergency department.
This project will test whether using the PERC score and the YEARS algorithm helps emergency doctors decide which adults need D-dimer blood tests or chest CT scans to diagnose pulmonary embolism.
-
Evaluating anticoagulation duration for pulmonary embolism in ICU patients
This study is testing how long ICU patients with serious pulmonary embolism should be treated with blood thinners to see how well it helps them recover.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.